MSD Animal Health Marks Commitment to Rabies Elimination Through Donation of NOBIVAC® Rabies Vaccines to Mission Rabies

Rahway, NJ., March 18, 2024 – MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK) has announced a continued commitment to rabies elimination through a donation of NOBIVAC® rabies vaccines to the Mission Rabies program, a charity initiative of the Worldwide Veterinary Service (WVS). The donations will continue over the next 5 years and support the full annual rabies vaccine requirements of this non-profit organization.

Rabies has a 100% fatality rate once symptoms develop and 99% of human cases are transmitted through dog bites, which is why eliminating rabies is crucial to safeguard human lives.i Despite being completely vaccine-preventable, rabies kills an estimated 59,000 people a year, many of whom are children.[i]

MSD Animal Health in partnership with Mission Rabies is dedicated to supporting the ambitious United Against Rabies Forum global goal of zero dog-mediated human rabies deaths by 2030. Spearheaded by the World Health Organization (WHO), the World Organisation for Animal Health (WOAH), and the Food and Agriculture Organization of the United Nations (FAO), the campaign focuses on three key pillars to work towards a world free of rabies: vaccination, awareness, and collaboration.

“MSD has contributed to global efforts to limit the transmission of rabies for more than a quarter of a century and this donation is yet another demonstration of our ongoing commitment, ” said David Sutton, Global Marketing Director, MSD Animal Health. “We will continue in our fight against rabies, and encourage others to take action against this deadly disease that impacts some of the most vulnerable populations, including children in high-risk regions.” 

 “Rabies, a dreadful and deadly disease, poses a significant threat to both humans and animals, particularly children,” emphasizes Luke Gamble, Founder and CEO of WVS. “Through our extensive projects, we’ve demonstrated that rabies can be eliminated through large-scale vaccination campaigns, offering crucial protection to vulnerable communities in some of the world’s most impoverished regions. We extend our heartfelt gratitude to MSD Animal Health for their unwavering support, and united, we remain steadfast in our mission to eliminate rabies once and for all.”

MSD Animal Health and Mission Rabies have worked in collaboration since 2013, resulting in over two million dogs vaccinated in countries around the world. This has included projects in India, Tanzania, Ghana, Uganda, Malawi, Sri Lanka and Cambodia. In May 2023 the partnership led to the vaccination of 75,000 dogs in Cambodia in just ten days, in a city where one to two children are estimated to die each week from rabies.

For more than 25 years, MSD Animal Health has supported efforts aimed at increasing canine rabies vaccination rates across the globe through its Afya Program ( The company has supplied Rabies Free Africa and Mission Rabies with over five million doses of life-saving vaccines to date, thanks to the engagement of vets around the world.

About MSD Animal Health

At MSD, known as Merck & Co., Inc., Rahway, N.J., USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of MSD. Through its commitment to The Science of Healthier Animals®, MSD Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. MSD Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. MSD Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit and connect with us on LinkedIn and X (formerly Twitter).

About Worldwide Veterinary Service

Worldwide Veterinary Service (WVS) is an international veterinary charity based in the UK. Set up by veterinarian Dr Luke Gamble in 2003, and became part of the Dogs Trust family in 2023, the charity provides veterinary support to animals in need and acts as a central veterinary resource for animal charities and non-profit organisations around the world. Since 2003 WVS has treated over 570,000 animals, sent over 11,000 parcels of veterinary aid, and trained over 7,700 veterinary professionals. WVS run their own projects, from neutering campaigns in Malawi to equine clinics in India, and training local and international vets at their centres in India, Africa, Thailand, and the Galápagos Islands. For more information, please visit  

About Mission Rabies

Mission Rabies was initially founded as an initiative by Worldwide Veterinary Service (WVS), a United Kingdom-based charity group that assists animals. Mission Rabies has a One Health approach driven by research to eliminate dog bite transmitted rabies (a disease that is estimated to kill 59,000 people annually). Launched in September 2013 with a mission to vaccinate 50,000 dogs against rabies across India, Mission Rabies teams have since then vaccinated over two million dogs and educated more than five million children in dog bite prevention in rabies endemic countries. For more information, visit

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (


i The World Health Organization. Rabies Fact Sheet. Accessed June, 2, 2023.